Connecting Through BCI-Enabled Communication: JAMA

Photo credit: Synchron

For people living with severe paralysis and other mobility-limiting conditions, an implantable brain-computer interface (BCI) device developed by Melbourne-born start-up Synchron is set to transform their digital connection and communication in everyday life. 

The Synchron Stentrode™ is a neuroprosthesis that transmits data from the brain, reading brain signals from within the blood vessels. A receiver device implanted in the chest collects those signals and sends them to an external decoder where that information is turned into specific commands. A life-changing innovation of Professors Tom Oxley and Nick Opie, the Stentrode device is now in the final stages of clinical trials. 

Research recently published by the Journal of the American Medical Association (JAMA) reported on Synchron’s results of its first peer-reviewed trial of the BCI in Australia. The incredible success of Stentrode in early-stage trials has underpinned Synchron’s significant capital raise to fast track the device to market. Following implantation in four patients, Stentrode remained safe and continued to perform strongly over a timeframe of 12 months. 

For those with significant paralysis or degenerative diseases like motor neurone disease which impact mobility, this technology is unparalleled. Stentrode has the potential to reopen the world of independent communication through wireless control of texting, social media and even smart home devices.

For end users, the ability to communicate with family and friends and perform everyday tasks like electronic banking is truly remarkable.

For more information, visit Synchron or download the JAMA research article.